Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Alex, Hofmann, Dirk, Hall, Lesley-Ann, Klebe, Sonja, Mountifield, Réme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079880/
https://www.ncbi.nlm.nih.gov/pubmed/33948072
http://dx.doi.org/10.20524/aog.2021.0582
_version_ 1783685309649649664
author Barnes, Alex
Hofmann, Dirk
Hall, Lesley-Ann
Klebe, Sonja
Mountifield, Réme
author_facet Barnes, Alex
Hofmann, Dirk
Hall, Lesley-Ann
Klebe, Sonja
Mountifield, Réme
author_sort Barnes, Alex
collection PubMed
description Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.
format Online
Article
Text
id pubmed-8079880
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-80798802021-05-03 Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis Barnes, Alex Hofmann, Dirk Hall, Lesley-Ann Klebe, Sonja Mountifield, Réme Ann Gastroenterol Case Report Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response. Hellenic Society of Gastroenterology 2021 2021-01-27 /pmc/articles/PMC8079880/ /pubmed/33948072 http://dx.doi.org/10.20524/aog.2021.0582 Text en Copyright: © 2021 Hellenic Society of Gastroenterology https://creativecommons.org/licenses/by-nc-sa/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Barnes, Alex
Hofmann, Dirk
Hall, Lesley-Ann
Klebe, Sonja
Mountifield, Réme
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
title Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
title_full Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
title_fullStr Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
title_full_unstemmed Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
title_short Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
title_sort ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079880/
https://www.ncbi.nlm.nih.gov/pubmed/33948072
http://dx.doi.org/10.20524/aog.2021.0582
work_keys_str_mv AT barnesalex ocrelizumabinducedinflammatoryboweldiseaselikeillnesscharacterizedbyesophagitisandcolitis
AT hofmanndirk ocrelizumabinducedinflammatoryboweldiseaselikeillnesscharacterizedbyesophagitisandcolitis
AT halllesleyann ocrelizumabinducedinflammatoryboweldiseaselikeillnesscharacterizedbyesophagitisandcolitis
AT klebesonja ocrelizumabinducedinflammatoryboweldiseaselikeillnesscharacterizedbyesophagitisandcolitis
AT mountifieldreme ocrelizumabinducedinflammatoryboweldiseaselikeillnesscharacterizedbyesophagitisandcolitis

Ejemplares similares